Science Explorer Back to mapMap

Lung Cancer Treatments and Mutations

Lung Cancer Treatments and Mutations is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 61k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the advancements in lung cancer research, particularly in understanding EGFR and ALK mutations, targeted therapy, resistance mechanisms to tyrosine kinase inhibitors, clinical trials evaluating different treatment regimens, genomic profiling for personalized medicine, and the development of treatment guidelines based on molecular biomarkers. The research also explores the concept of oncogene addiction and its implications for targeted therapies.

  • EGFR Mutations
  • Targeted Therapy
  • ALK Inhibitors
  • Resistance Mechanisms
  • Clinical Trials
  • Genomic Profiling
  • Chemotherapy Regimens
  • Biomarker Analysis
  • Treatment Guidelines
  • Oncogene Addiction
Research works
61k
fractional, since 1950
In the world top 10%
6.3k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+12%
the tick is no change
Largest producer
China
33% of the 10 largest, 2022-now
Lung Cancer Treatments and Mutations

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Lung Cancer Treatments and Mutations research?

By volume, China and the United States publish the most (4k and 3.5k works in 2022-now).

By volume, 2022-now

  1. 1 China 4k works
  2. 2 United States 3.5k works
  3. 3 Japan 1.1k works
  4. 4 Italy 544 works
  5. 5 Germany 519 works
  6. 6 India 514 works
  7. 7 United Kingdom 506 works
  8. 8 France 465 works
  9. 9 South Korea 436 works
  10. 10 Spain 373 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 33.2%United States: 29.5%Japan: 9.3%Italy: 4.5%6 others listed: 23.5%33%largest
China3,978 · 33.2%United States3,537 · 29.5%Japan1,118 · 9.3%Italy544 · 4.5%6 others listed2,814 · 23.5%

Shares of the rows listed above, not of the whole node.

Which institutions lead Lung Cancer Treatments and Mutations research?

By volume in 2022-now, Harvard University publishes the most Lung Cancer Treatments and Mutations research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Sun Yat-sen University.

Who are the leading researchers in Lung Cancer Treatments and Mutations?

The most-cited researchers publishing on Lung Cancer Treatments and Mutations include Ahmedin Jemal, Rebecca L. Siegel and Freddie Bray.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Rebecca L. Siegel United States 582k citations
  3. 3 Freddie Bray France 550k citations
  4. 4 Eric S. Lander United States 524k citations
  5. 5 Jacques Ferlay France 486k citations
  6. 6 George Davey Smith United Kingdom 435k citations
  7. 7 Stacey L. Gabriel United States 402k citations
  8. 8 Guido Kroemer France 386k citations
  9. 9 Bert Vogelstein United States 373k citations
  10. 10 Gad A. Getz United States 364k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Lung Cancer Treatments and Mutations?

The most cited paper in Lung Cancer Treatments and Mutations is "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)" (E. A. Eisenhauer, P. Therasse, Jan Bogaerts et al., 2008), with 30,125 citations. Next come "The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology" (16,252) and "New Guidelines to Evaluate the Response to Treatment in Solid Tumors" (15,773).

Most cited papers
#PaperReleasedCitations
1 New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. A. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer 27 Dec 2008 30,125
2 The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology N.K. Aaronson, Sam Hjelmeland Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute 3 Mar 1993 16,252
3 New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute 2 Feb 2000 15,773
4 Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas James Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine 19 May 2004 11,595
5 Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening The National Lung Screening Trial Research Team · New England Journal of Medicine Open access 29 Jun 2011 11,266
All 99 most cited papers, with filters and sorting

Where is Lung Cancer Treatments and Mutations research done?

The largest centres of Lung Cancer Treatments and Mutations research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Plainview and Kashiwa.

Largest cities, 2022-now

  1. 1 BeijingChina 506 works
  2. 2 ShanghaiChina 401 works
  3. 3 GuangzhouChina 364 works
  4. 4 New YorkUnited States 298 works
  5. 5 SeoulSouth Korea 258 works
  6. 6 TokyoJapan 256 works
  7. 7 ChengduChina 181 works
  8. 8 BostonUnited States 180 works
  9. 9 HangzhouChina 178 works
  10. 10 NanjingChina 177 works

Where it is the local speciality

  1. PlainviewUS · 46.5 works41×
  2. KashiwaJP · 46.7 works36×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Lung Cancer Treatments and Mutations than the world average.

See Lung Cancer Treatments and Mutations on the map

Where is the best place to study Lung Cancer Treatments and Mutations?

Among universities, judged by research, Harvard University, Cornell University and Université Paris-Saclay score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 15.86%fractional works in this field (log) →share of work in the world top 10% →Université Paris-Sac…Cornell UniversityKettering UniversityHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 81.420.3%4.5×185 -12.3%
2Cornell UniversityUnited States 71.320.9%2.8×48 +7.1%
3Université Paris-SaclayFrance 67.625.2%2.0×16 +25.6%
4Kettering UniversityUnited States 62.720.5%17.9×8 +95.2%
5Sun Yat-sen UniversityChina 61.28.9%5.4×143 +16.0%
6Yale UniversityUnited States 59.914.9%3.6×50 +9.5%
7Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 59.89.8%11.2×152 +7.2%
8Sichuan UniversityChina 59.110.6%4.2×123 +42.8%
9Yonsei UniversitySouth Korea 59.113.0%4.7×55 +29.1%
10Sungkyunkwan UniversitySouth Korea 58.814.5%7.4×66 -5.5%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Lung Cancer Treatments and Mutations, country by country

Is Lung Cancer Treatments and Mutations research growing?

Output in 2022-2025 was 12% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Lung Cancer Treatments and Mutations.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Lung Cancer Treatments and Mutations as a percentage of every work published that year, 0.064% in 2024.

still counting0.050%0.10%Lung Cancer Treatments and Mutations0.067% in 202519801990200020102020

Fractional works of Lung Cancer Treatments and Mutations over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Lung Cancer Treatments and Mutations9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Lung Cancer Treatments and Mutations. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.